Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00506207
Other study ID # NCCCTS-06-166
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received July 23, 2007
Last updated July 23, 2007
Start date September 2006
Est. completion date December 2009

Study information

Verified date July 2007
Source National Cancer Center, Korea
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study is an open-label, single center, and a dose-escalating phase I study to determine the maximal tolerated dose and the recommended dose of S-1 combined with irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric carcinoma.


Description:

Dose level and escalating schedule are followings;

- S-1 (level 1/2, 3/4, 5/6: 60, 70, 80 mg/m2/day) every 12-h p.o. on days 1(evening)-15 (morning)

- Irinotecan (level 1,2/3, 4/5, 6: 120, 130, 140, 150 mg/m2) mixed in d5w or normal saline 500 ml iv over 90 min on day 1

- Oxaliplatin 85 mg/m2 fixed dose mixed in d5w 250 ml iv infusion over 2-h on day 1

Treatment will be administered every 3 weeks. Start at dose level 1. Thereafter, dose level 2, 3, 4, 5, and 6. If dose-limiting toxicity (DLT) occurs at dose level 1, dose level at -1 will follow

Dose escalation will be continued until more than one-third of the patients in a given cohort show dose-limiting toxicity (DLT) during treatment cycle 1. At least three patients will be enrolled in each cohort. Before escalating to the next dose level, all three patients should have received at least one treatment cycle. If none of the first three treated patients develops DLT in the first cycle at a specific dose level, dose escalation will be continued. If one of the first three treated patients develops DLT at any dose level, then three additional patients are to be entered on the same dose level. If only one in six patients at a given level experiences a DLT, escalation will proceed. The MTD is defined as the dose level at which at least one-third of patients experienced a DLT. The RD for the subsequent phase II study is defined as the preceding dose level before the MTD is attained. Intra-patient dose escalation will not be permitted. Treatment will be continued in the absence of disease progression or unacceptable toxicity with maximum 12 cycles. For purpose of determining the MTD, only DLT occurring during the first cycle of therapy will be considered.

DLTs are defined as any of following;

- Grade 4 neutropenia lasting at least 7 days or grade 3 or 4 neutropenia associated with fever  38.3C as single axillary temperature or 38 C for 1-h

- Grade 4 thrombocytopenia

- Grade 3 or 4 non-hematological toxicity except alopecia, and nausea/vomiting

- Grade 3 or 4 nausea/vomiting not reduced to grade 1 with aggressive antiemetic support

- Inability of the patient to take 75% of the planned chemotherapy dose during the treatment period


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 23
Est. completion date December 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed unresectable or metastatic colorectal or gastric carcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Measurable disease, according to the RECIST criteria or non-measurable disease Measurable lesions

- Previous adjuvant, palliative chemotherapy including 5-FU, oxaliplatin and irinotecan, molecular targeted therapy and/or radiotherapy is allowed

- Adequate major organ functions

- Patients should sign a written informed consent before study entry

Exclusion Criteria:

- Prior history of peripheral neuropathy

- Inadequate cardiovascular

- Serious concurrent infection or nonmalignant illness

- Other malignancy within the past 3 years except non-melanomatous skin cancer or carcinoma in situ of the cervix

- Psychiatric disorder that would preclude compliance

- Pregnant, nursing women or patients with reproductive potential without contraception

- Patients receiving a concomitant treatment with drugs interacting with S-1 such as flucytosine, phenytoin, or warfarin et al.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
S-1, Irinotecan, Oxaliplatin


Locations

Country Name City State
Korea, Republic of National Cancer Center Korea Goyang Gyeonggi

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Center, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity measured by NCICTC v.3 During treatment
Primary Blood level of irinotecan and S-1 and their metabolites At 1st cycle
Secondary Maximal response rate, progression-free survival, survival
See also
  Status Clinical Trial Phase
Completed NCT02244632 - Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer Phase 1/Phase 2
Completed NCT01417611 - The Usefulness of I-scan in Screening Colonoscopy N/A
Completed NCT02057471 - Intravenous Iron: Measuring Response in Anemic Surgical Patients Phase 4
Terminated NCT01074333 - An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment N/A
Recruiting NCT05953662 - Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer N/A
Completed NCT01959269 - Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Recruiting NCT04160832 - Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps
Terminated NCT02961283 - Study of ASN003 in Subjects With Advanced Solid Tumors Phase 1
Suspended NCT02121405 - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Phase 3
Active, not recruiting NCT03936530 - Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
Terminated NCT03724071 - Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Phase 1/Phase 2
Active, not recruiting NCT02882620 - Enhancing Prevention Pathways Toward Tribal Colorectal Health N/A
Completed NCT00906997 - Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy N/A
Completed NCT00188331 - Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy N/A
Completed NCT04786704 - A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
Terminated NCT02384850 - Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer Phase 1
Completed NCT01288833 - Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study N/A
Completed NCT00001693 - Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers Phase 1
Recruiting NCT03280407 - NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer Phase 2